Factor Xa inhibitors
- 1 July 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (7), 931-953
- https://doi.org/10.1517/13543776.9.7.931
Abstract
Factor Xa is a key enzyme in the production of thrombin from its precursor prothrombin and is an important target for antithrombotic drug development. The patent literature for the last four to five years illustrates a variety of peptide and non-peptide Factor Xa inhibitors, including small proteins isolated from natural sources, rationally designed peptides and peptidomimetics based on substrate cleavage sites, and non-peptide small molecules derived from screening and rational design. This report reviews the status of the patent literature in the field of Factor Xa inhibitors through 1998.Keywords
This publication has 44 references indexed in Scilit:
- Potential advantages of direct-acting thrombin inhibitorsCoronary Artery Disease, 1996
- Challenges in the development of orally bioavailable thrombin active site inhibitorsBlood Coagulation & Fibrinolysis, 1995
- Thrombin active site inhibitorsBioorganic & Medicinal Chemistry, 1995
- Novel Antithrombotic Drugs in DevelopmentDrugs, 1995
- Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic AgentsExpert Opinion on Investigational Drugs, 1995
- Chapter 8. Anticoagulant Strategies Targeting Thrombin and Factor XaPublished by Elsevier ,1995
- Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)Circulation, 1994
- Specific Thrombin Inhibitors in VivoAnnals of the New York Academy of Sciences, 1994
- Cell Mediated Events that Control Blood Coagulation and Vascular InjuryAnnual Review of Cell Biology, 1993
- The coagulation cascade: initiation, maintenance, and regulationBiochemistry, 1991